Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Vivos Therapeutics (VVOS) Non Operating Income (2022 - 2025)

Vivos Therapeutics (VVOS) has disclosed Non Operating Income for 4 consecutive years, with -$680000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Non Operating Income fell 3677.78% to -$680000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was -$918000.0, a 1539.29% decrease, with the full-year FY2024 number at -$110000.0, up 48.11% from a year prior.
  • Non Operating Income was -$680000.0 for Q3 2025 at Vivos Therapeutics, down from -$166000.0 in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $51000.0 in Q1 2023 to a low of -$680000.0 in Q3 2025.
  • A 4-year average of -$90800.0 and a median of -$36000.0 in 2022 define the central range for Non Operating Income.
  • Peak YoY movement for Non Operating Income: surged 234.21% in 2023, then plummeted 3677.78% in 2025.
  • Vivos Therapeutics' Non Operating Income stood at -$79000.0 in 2022, then soared by 82.28% to -$14000.0 in 2023, then plummeted by 385.71% to -$68000.0 in 2024, then crashed by 900.0% to -$680000.0 in 2025.
  • Per Business Quant, the three most recent readings for VVOS's Non Operating Income are -$680000.0 (Q3 2025), -$166000.0 (Q2 2025), and -$4000.0 (Q1 2025).